Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Verici Dx Plc ( (GB:VRCI) ) just unveiled an announcement.
Verici Dx reported record revenues of $3.3 million for 2024, driven by a commercial contract with Thermo Fisher for its PTRA test. The company achieved several operational milestones, including securing Medicare coverage for its Tutivia™ assay and receiving CLIA certification, which enhances its testing capabilities across the US. Despite financial challenges, including a need for additional funding by July 2025, Verici Dx is optimistic about its future growth, particularly in the post-transplant market, which is valued at approximately $900 million. The company aims to expand its market presence by addressing unmet needs in areas like delayed graft function and BK nephropathy.
More about Verici Dx Plc
Verici Dx Plc is a company specializing in advanced clinical diagnostics for organ transplants, focusing on developing diagnostic assays such as the PTRA (Pre Transplant Risk Assessment) test. The company is engaged in the healthcare industry, particularly in the transplant care sector, and collaborates with partners like Thermo Fisher to enhance its market reach.
Average Trading Volume: 728,167
Technical Sentiment Signal: Sell
Current Market Cap: £2.73M
For an in-depth examination of VRCI stock, go to TipRanks’ Overview page.